Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
- 2.5k Downloads
It is well established that only a fraction of Aβ peptides in the brain of Alzheimer’s disease (AD) patients start with N-terminal aspartate (Aβ1D) which is generated by proteolytic processing of amyloid precursor protein (APP) by BACE. N-terminally truncated and pyroglutamate modified Aβ starting at position 3 and ending with amino acid 42 [Aβ3(pE)–42] have been previously shown to represent a major species in the brain of AD patients. When compared with Aβ1–42, this peptide has stronger aggregation propensity and increased toxicity in vitro. Although it is unknown which peptidases remove the first two N-terminal amino acids, the cyclization of Aβ at N-terminal glutamate can be catalyzed in vitro. Here, we show that Aβ3(pE)–42 induces neurodegeneration and concomitant neurological deficits in a novel mouse model (TBA2 transgenic mice). Although TBA2 transgenic mice exhibit a strong neuronal expression of Aβ3–42 predominantly in hippocampus and cerebellum, few plaques were found in the cortex, cerebellum, brain stem and thalamus. The levels of converted Aβ3(pE)-42 in TBA2 mice were comparable to the APP/PS1KI mouse model with robust neuron loss and associated behavioral deficits. Eight weeks after birth TBA2 mice developed massive neurological impairments together with abundant loss of Purkinje cells. Although the TBA2 model lacks important AD-typical neuropathological features like tangles and hippocampal degeneration, it clearly demonstrates that intraneuronal Aβ3(pE)–42 is neurotoxic in vivo.
KeywordsAmyloid Transgenic model Neuron death Neurodegeneration Behavior N-truncated Abeta
Long-standing evidence shows that progressive cerebral deposition of Aβ plays a seminal role in the pathogenesis of Alzheimer’s disease (AD). There has been great interest, therefore, in understanding the proteolytic processing of APP and the enzymes responsible for cleaving at the N- and C-termini of the Aβ region. Besides Aβ peptides starting with an aspartate at position 1, a variety of different N-truncated Aβ peptides has been identified in AD brains. Ragged peptides with a major species beginning with phenylalanine at position 4 of Aβ have been reported as early as 1985 by Masters et al. . This finding has been disputed, as no N-terminal sequence could be obtained from cores purified in a sodium dodecyl sulfate-containing buffer, suggesting that the N-terminus is blocked [16, 59]. In 1992, Mori et al. first described the presence of Aβ3(pE) using mass spectrometry of purified Aβ protein from AD brains, explaining the difficulties in sequencing the amino-terminus . They reported that only 10–15% of the total Aβ isolated by this method begins at position 3 with Aβ3(pE). Saido et al.  showed for the first time that Aβ3(pE) represents an important fraction of Aβ peptides in AD brain, which was later verified by other reports using AD and Down’s syndrome post-mortem brain tissue [18, 19, 23, 25, 28, 29, 38, 45, 46, 49, 53, 63]. N-terminal deletions in general enhance aggregation of β-amyloid peptides in vitro . Aβ3(pE) has a higher aggregation propensity [20, 55], and stability , and shows an increased toxicity compared with full-length Aβ .
Mouse models mimicking AD-typical pathology, such as deficits in synaptic transmission , changes in behavior, differential glutamate responses, and deficits in long-term potentiation are typically based on the overexpression of full-length amyloid precursor protein (APP) . Learning deficits [2, 21, 43, 48] were evident in different APP models, however, Aβ-amyloid deposition did not correlate with the behavioral phenotype . In the past, Aβ has been regarded as acting extracellularly, whereas recent evidence points to toxic effects of Aβ in intracellular compartments [64, 68]. In addition, another concept favors that toxic forms of Aβ are soluble oligomers and β-sheet containing amyloid fibrils [26, 58]. It has been demonstrated that soluble oligomeric Aβ42, but not plaque-associated Aβ correlates best with cognitive dysfunction in AD [37, 42]. Oligomeres are formed, preferentially, intracellularly within neuronal processes and synapses rather than extracellularly [60, 66]. Previously, we have reported that intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the hippocampus , the frontal cortex , and the cholinergic system  of APP/PS1KI mice expressing transgenic human mutant APP751 including the Swedish and London mutations on a murine knock-in (KI) Presenilin 1 (PS1) background with two FAD-linked mutations (PS1M233T and PS1L235P). The APP/PS1KI mice exhibit robust and learning deficits at the age of 6 months , age-dependent axonopathy , neuron loss in hippocampus CA1 together with synaptic deficits, and hippocampus atrophy coinciding with intraneuronal aggregation of N-terminal-modified Aβ variants .
The APP/PS1KI mouse model exhibits a large heterogeneity of N-truncated Aβ x–42 variants . It is impossible to decipher the true toxic peptides from those, which might only co-precipitate. Therefore, we generated a new mouse model expressing only N-truncated Aβ3(pE) in neurons, and demonstrate for the first time that this peptide is neurotoxic in vivo inducing neuron loss and an associated neurological phenotype.
Materials and methods
The generation of murine thyrotropin-releasing hormone-Aβ fusion protein mTRH-Aβ3Q–42 was essentially as described elsewhere . The respective cDNA was inserted into the vector pUC18 containing the murine Thy-1 sequence applying standard molecular biology techniques and verified by sequencing. The transgenic mice were generated by male pronuclear injection of fertilized C57Bl/6J oocytes (PNI, generated by genOway, Lyon, France). The resulting offspring were further characterized for transgene integration by PCR analysis and after crossing to C57Bl/6J wildtype mice for transgene expression by RT-PCR. The line with the highest transgene mRNA expression was selected for further breeding (named TBA2).
The generation of APP/PS1KI mice (a generous gift by Dr. Laurent Pradier, Sanofi-Aventis, Paris) has been described previously . All mice named as PS1KI were homozygous for the mutant PS1 knock-in transgene (KI). The APP/PS1KI mice harbored one hemizygous APP751SL transgene in addition to homozygous PS1KI. The mice were backcrossed for more than ten generations on a C57BL/6J genetic background. APP/PS1KI were crossed with PS1KI mice generating again APP/PS1KI and PS1KI mice, therefore, all offspring carried homozygous PS1KI alleles. All animals were handled according to the German guidelines for animal care.
Immunohistochemistry and histology
Mice were anaesthetized and transcardially perfused with ice-cold phosphate-buffered saline (PBS) followed by 4% paraformaldehyde. Brain samples were carefully dissected and post-fixed in 4% phosphate-buffered formalin at 4°C. Immunohistochemistry was performed on 4 μm paraffin sections. The following antibodies were used: 4G8 (Aβ17-24, Signet), GFAP (Chemicon), Iba1 (Waco), ubiquitin (DAKO), AT8 (Innogennetics), PS199 (Biosource), activated caspase-3 (Chemicon), calbindin (Swant), and 2 antibodies against Aβ with pyroglutamate at position 3 (a generous gift of Dr. Takaomi Saido ; American Research Products). Biotinylated secondary anti-rabbit and anti-mouse antibodies (1:200) were purchased from DAKO. Staining was visualized using the ABC method, with a Vectastain kit (Vector Laboratories) and diaminobenzidine as chromogen. Counterstaining was carried out with hematoxylin. For fluorescent staining, AlexaFluor488- and AlexaFluor594-conjugated antibodies (Molecular Probes), was used.
Quantification of Aβ x–42 and Aβ3(pE) by ELISA
Brains were weight in frozen state and directly homogenized in a Dounce-homogenizer in 2.5 ml 2% SDS, containing complete protease inhibitor (Roche). Homogenates were sonified for 30 s and subsequently centrifuged at 80,000g for 1 min at 4°C. Supernatants were directly frozen at −80°C. The resulting pellets were resuspended in 0.5 ml 70% formic acid (FA) and sonified for 30 s. Formic acid was neutralized with 9.5 ml 1 M Tris and aliquots were directly frozen at −80°C. SDS lysates were used in a 10-fold dilution for both Aβ x–42 and AβN3(pE) ELISAs. Formic acid lysates were used in a 10-fold dilution for the Aβ x–42 measurement. For Aβ3(pE) measurements undiluted FA lysates were used. ELISA measurements were performed according to the protocol of the manufacturer (IBL Co., Ltd. Japan; cat. no. JP27716 and JP27711). For statistical analyses, Aβ x–42 and Aβ3(pE) concentrations resulting from SDS and formic acid extractions were cumulated.
Differences between the groups were tested with one-way analysis of variance (ANOVA) followed by unpaired t tests. All data are given as mean ± SEM. Significance levels of unpaired t tests are given as follows: ***P < 0.001; **P < 0.01; *P < 0.05. Survival rate was calculated by the Log-rank test. All calculations were performed using GraphPad Prism version 4.03 for Windows (GraphPad Software, San Diego, CA, USA).
Generation of transgenic TBA2 mouse line
Phenotypic characterization of TBA2 mice
Quantification of Aβ x–42 and Aβ3(pE) levels
Neuropathological assessment of TBA2 mice
Distribution and semi-quantitative description of intraneuronal and plaque-associated Aβ pathology based on 4G8 immunostaining
Purkinje cell layer
Granule cell layer
Mice transgenic for the human APP gene have been proven valuable model systems for AD research. Early pathological changes, including deficits in synaptic transmission , changes in behavior, differential glutamate responses, and deficits in long-term potentiation  have been reported in several studies. In addition, learning deficits [2, 15, 21, 43, 48] and reduced brain volume  were evident in transgenic APP models. Interestingly, extracellular amyloid deposition did not correlate with the behavioral phenotype [22, 67]. These deficits occurred well before plaque deposition became prominent and may, therefore, reflect early pathological changes, likely induced by intraneuronal APP/Aβ mistrafficking or intraneuronal Aβ accumulation (reviewed in ). The coincidence of intracellular Aβ with behavioral deficits supporting an early role of intracellular Aβ has been recently demonstrated in a mouse model containing the Swedish and Arctic mutations [27, 34]. In accordance with these findings, we have previously shown that intraneuronal Aβ accumulation precedes plaque formation in transgenic mice expressing mutant APP695 with the Swedish, Dutch, and London mutations in combination with mutant PS-1 M146L. These mice displayed abundant intraneuronal Aβ immunoreactivity in hippocampal and cortical pyramidal neurons . An even more pronounced phenotype was observed in another transgenic mouse model, expressing Swedish and London mutant APP751 together with mutant PS-1 M146L . In young mice, a strong intraneuronal Aβ staining was detected in vesicular structures in somatodendritic and axonal compartments of pyramidal neurons and an attenuated neuronal immunoreactivity with increasing age. The intraneuronal immunoreactivity declined with increased plaque accumulation , a finding which was also reported in Down’s syndrome patients, where the youngest patients displayed the strongest immunoreactivity . The neuronal loss in CA1 of the hippocampus did not correlate with the amount of extracellular Aβ [4, 8]. The same observation has been reported in the APP/PS1M146L model . Hippocampal neuron loss has also been reported in the APP23 mouse model , however whether intraneuronal Aβ contributes to the neuron loss in this model is not clear. The triple-transgenic mouse model expresses mutant APP in combination with mutant PS-1 and mutant Tau protein. These mice displayed early synaptic dysfunction before plaque or tangle deposition was evident, together with early intraneuronal Aβ immunoreactivity preceding plaque deposition. Tau and Aβ immunoreactivity colocalized in hippocampal neurons, which might imply that early intraneuronal Aβ accumulation could affect Tau pathology . All these AD mouse models express full-length APP, and also C-terminal fragments and Aβ peptides after cleavage. It is, therefore, difficult to decipher the pathological function of specific Aβ peptides.
In order to specifically investigate the neurotoxicity of Aβ3pE–42 generation in vivo, we have generated transgenic mice expressing Aβ3Q–42 starting at position 3 with glutamine and ending with position 42 (TBA2 mouse line). Owing to the replacement of N-terminal glutamate by glutamine, the Aβ peptides are more prone to conversion into pyroglutamate . The severity of the neurological phenotype observed in TBA2 mice, accompanied with the Purkinje cell loss and premature mortality reflects the in vivo toxicity of Aβ3(pE)–42. However, we cannot rule out that unprocessed Aβ3Q–42 has been stabilized by Aβ3(pE)–42 accumulation, and might also contribute to the observed neurological phenotype. In addition, the level of Aβ3(pE)–42 in 6-month-old APP/PS1KI mice was comparable to that of 2-month-old TBA2 mice. However, 85% of Aβ peptides in the APP/PS1KI mice terminated at position 42, the N-terminus shows a large heterogeneity including Aβ3(pE). The time point of high levels of Aβ3(pE)–42 coincided with the onset of behavioral deficits in both mouse models. In addition, only a fraction of Purkinje cells showed abundant levels of intracellular Aβ3(pE) accumulation leading to the assumption that only those are prone for degeneration (Fig. 4). We have previously shown that at 6 months, the APP/PS1KI mice exhibit a neuron loss in CA1 of the hippocampus [4, 8], the frontal cortex , and in distinct cholinergic nuclei . Recently, a transgenic mouse model expressing human APP with the 714 austrian mutation has been reported showing intraneuronal Aβ accumulation correlating with brain atrophy . Overall, the pathological events seen in the APP/PS1KI mouse model might be at least partly triggered by Aβ3(pE)–42 accumulation however the TBA2 mouse model is the only one expressing Aβ3(pE)–42 without any of the other Aβ peptides.
Amyloid precursor protein transgenic mouse models have been reported to show no  or low Aβ3(pE) levels . Maeda et al. have demonstrated that the localization and abundance of [11C]PIB autoradiographic signals were closely associated with those of amino-terminally truncated and modified Aβ3pE deposition in AD and different APP transgenic mouse brains, implying that the detectability of amyloid by [11C]PIB-PET is dependent on the accumulation of specific Aβ subtypes . There is an interesting coincidence of considerable amounts of Aβ3(pE) and massive neuron loss in the APP/PS1KI mouse model [1, 8]. An emerging role of intracellular Aβ accumulation has been previously shown in human AD [13, 17]. It has been observed that Aβ localizes predominantly to abnormal endosomes , multivesicular bodies, and within pre- and postsynaptic compartments [31, 61]. Takahashi et al. demonstrated that Aβ42 aggregates into oligomers within endosomal vesicles and along microtubules of neuronal processes, both in Tg2576 neurons with time in culture, as well as in Tg2576 and human AD brain . In good agreement with these reports, we observed that Aβ is also localized in the late endosomal/lysosomal compartment in the TBA2 model. Owing to the large heterogeneity of N-truncated Aβ x–42 peptides in the APP/PS1KI model, it is impossible to study the role of a single Aβ variant. In the TBA2 model, however, we were able to demonstrate the intraneuronal Aβ3(pE)–42 aggregation induced neuron loss without contribution of extracellular Aβ aggregation.
N-truncated Aβ3(pE) peptides have been identified by several groups from AD brains [18, 19, 23, 25, 28, 29, 38, 41, 45, 46, 49, 52, 53, 63]. In addition, other N-terminal truncated peptides have been identified such as Aβ5–40/42 , Aβ11–40/42 [32, 33], and Flemish and Dutch N-terminally truncated amyloid beta peptides . Cai et al. have demonstrated that secretion of Aβ1–40/42 and Aβ11–40/42 is abolished in BACE1−/− neurons establishing that BACE1 is the principal β-secretase for endogenous APP in neurons. Although Aβ11–40/42 peptides have been observed in neuronal cultures and in the brains of patients with AD, the involvement of these peptides in its pathogenesis remains to be elusive . In general, N-terminal deletions enhance aggregation of β-amyloid peptides in vitro . Aβ3(pE) has a higher aggregation propensity [20, 55] and stability , and shows an increased toxicity compared with full-length Aβ . It has been suggested that N-truncated Aβ peptides are formed directly by BACE and not through a progressive proteolysis of full-length Aβ1–40/42 .
In in vitro experiments Schilling et al. have shown that the cyclization of glutamate at position 3 of Aβ is driven enzymatically by glutaminyl cyclase (QC) . In addition, it has been shown that QC inhibition significantly reduced Aβ3(pE) formation, emphasizing the importance of QC activity during the cellular maturation of pyroglutamate-containing peptides. The pharmacological inhibition of QC activity by the QC inhibitor P150, which significantly reduced the level of Aβ3(pE) in vitro  and in vivo  suggests that QC inhibition might serve as a new therapeutic approach to rescue Aβ3(pE) triggered neurodegeneration in human disorders.
Aβ accumulation has an important function in the etiology of AD with its typical clinical symptoms, such as memory impairment and changes in personality. However, the mode of this toxic activity is still a matter of scientific debate. Previously, we have shown that the APP/PS1KI mouse model develops severe learning deficits at 6 months of age correlating with a CA1 neuron loss and an atrophy of the hippocampus [4, 8], together with a drastic reduction of long-term potentiation and disrupted paired pulse facilitation. This was accompanied by reduced levels of pre- and post-synaptic markers. We also observed that intraneuronal and not plaque-associated Aβ including N-modified Aβ3(pE)–42 species increased and coincided well with CA1 neuron loss, however the dominant species was Aβ1–42 in the APP/PS1KI model. In good agreement with this study, we could show for the first time that intraneuronal Aβ3(pE)–42 accumulation is sufficient for triggering neuron death and inducing an associated neurological phenotype in a novel transgenic mouse model (TBA2 mice). The Aβ staining in the cerebellum was completely restricted to the intraneuronal compartment further supporting the notion that intraneuronal pathology is instrumental in neuron loss and that extracellular plaque deposition has no drastic effect on cell survival.
Financial support was provided by the European Commission, Marie Curie Early Stage Training, MEST-CT-2005-020013 (NEURAD), Alzheimer Ph.D. Graduate School, the Research program of the Faculty of Medicine, Georg-August-University Göttingen and Alzheimer Forschung Initiative e.V. (to O.W.) and a Klaus Murmann-Ph.D.-scholarship from the Foundation of German Businesses (to H.B.). Disclosure statement: H.U.D. is a shareholder, H.C. and S.S. are employees, T.A.B. is a scientific consultant of Probiodrug.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Representative video of a wildtype mouse at 2 months of age suspended at the tail. The mouse shows normal motor coordination (WMV 2036 kb)
Representative video of a TBA2 mouse at 2 months of age suspended at the tail. The mouse shows neurological deficits (WMV 2458 kb)
Representative video of a TBA2 mouse at 2 months of age. The mouse has difficulties to redress its balance and shows severe neurological deficits (WMV 2247 kb)
- 3.Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA, Langui D, Duyckaerts C, Tremp G, Pradier L (2003) Time sequence of maturation of dystrophic neuritis associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol 184:247–263PubMedCrossRefGoogle Scholar
- 8.Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L (2004) Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165:1289–1300PubMedGoogle Scholar
- 10.Christensen DZ, Bayer TA, Wirths O (2008) Intracellular Abeta triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer’s disease. Neurobiol Aging. doi: 10.1016/j.neurobiolaging.2008.07.022
- 14.Demeester N, Mertens C, Caster H, Goethals M, Vandekerckhove J, Rosseneu M, Labeur C (2001) Comparison of the aggregation properties, secondary structure and apoptotic effects of wild-type, Flemish and Dutch N-terminally truncated amyloid beta peptides. Eur J Neurosci 13:2015–2024PubMedCrossRefGoogle Scholar
- 21.Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O’Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97–100PubMedCrossRefGoogle Scholar
- 29.Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE (2001) Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer’s disease brains. J Biol Chem 276:12991–12998PubMedCrossRefGoogle Scholar
- 33.Liu K, Solano I, Mann D, Lemere C, Mercken M, Trojanowski JQ, Lee VM (2006) Characterization of Abeta11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer’s disease. Acta Neuropathol (Berl) 112:163–174 (Epub 2006 Jun 2001)CrossRefGoogle Scholar
- 35.Maeda J, Ji B, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori M, Higuchi M, Suhara T (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by PET. J Neurosci 27:10957–10968PubMedCrossRefGoogle Scholar
- 39.Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274:6483–6492PubMedCrossRefGoogle Scholar
- 43.Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129–10140PubMedCrossRefGoogle Scholar
- 45.Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, Borghi R, Giliberto L, Armirotti A, D’Arrigo C, Bachi A, Cattaneo A, Canale C, Torrassa S, Saido TC, Markesbery W, Gambetti P, Tabaton M (2005) beta-Amyloid is different in normal aging and in alzheimer disease. J Biol Chem 280:34186–34192PubMedCrossRefGoogle Scholar
- 46.Piccini A, Zanusso G, Borghi R, Noviello C, Monaco S, Russo R, Damonte G, Armirotti A, Gelati M, Giordano R, Zambenedetti P, Russo C, Ghetti B, Tabaton M (2007) Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype. Arch Neurol 64:738–745PubMedCrossRefGoogle Scholar
- 50.Russo C, Salis S, Dolcini V, Venezia V, Song XH, Teller JK, Schettini G (2001) Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer’s disease and Down’s syndrome brain. Neurobiol Dis 8:173–180PubMedCrossRefGoogle Scholar
- 56.Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer’s disease-like pathology. Nat Med 14:1106–1111PubMedCrossRefGoogle Scholar
- 57.Schmitz C, Rutten BP, Pielen A, Schafer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Rezaie P, Korr H, Steinbusch HW, Pradier L, Bayer TA (2004) Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer’s disease. Am J Pathol 164:1495–1502PubMedGoogle Scholar
- 65.Van Broeck B, Vanhoutte G, Pirici D, Van Dam D, Wils H, Cuijt I, Vennekens K, Zabielski M, Michalik A, Theuns J, De Deyn PP, Van der Linden A, Van Broeckhoven C, Kumar-Singh S (2008) Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer’s disease. Neurobiol Aging 29:241–252PubMedCrossRefGoogle Scholar
Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.